Titre
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Eastell, R.
Auteure/Auteur
Lang, T.
Auteure/Auteur
Boonen, S.
Auteure/Auteur
Cummings, S.
Auteure/Auteur
Delmas, P.D.
Auteure/Auteur
Cauley, J.A.
Auteure/Auteur
Horowitz, Z.
Auteure/Auteur
Kerzberg, E.
Auteure/Auteur
Bianchi, G.
Auteure/Auteur
Kendler, D.
Auteure/Auteur
Leung, P.
Auteure/Auteur
Man, Z.
Auteure/Auteur
Mesenbrink, P.
Auteure/Auteur
Eriksen, E.F.
Auteure/Auteur
Black, D.M.
Auteure/Auteur
HORIZON Pivotal Fracture, Trial
Auteure/Auteur
Contributrices/contributeurs
HORIZON Pivotal Fracture, Trial
Black, D.
Cummings, S.
Delmas, P.
Eastell, R.
Reid, I.
Boonen, S.
Cauley, J.
Cosman, F.
Lakatos, P.
Leung, PC.
Man, Z.
Eriksen, EF.
Mesenbrink, P.
Lau, E.
Jasqui, S.
Mautalen, C.
Rosario-Jansen, T.
Caminis, J.
Raisz, L.
Bauer, P.
Compston, J.
DeMets, D.
Hirschberg, R.
Johnell, O.
Ralston, S.
Wallace, R.
Farkough, M.
Flood, M.
Bauer, D.
Palermo, L.
Lang, T.
Kerzberg, E.
Man, Z.
Mautalen, C.
Rosario-Jansen, T.
Caminis, J.
Raisz, L.
Bauer, P.
Compston, J.
DeMets, D.
Hirschberg, R.
Johnell, O.
Ralston, S.
Wallace, R.
Farkough, M.
Flood, M.
Bauer, D.
Palermo, L.
Lang, T.
Kerzberg, E.
Man, Z.
Mautalen, C.
Ridruejo, M.
Tate, G.
Velasco, J.
Hooper, M.
Kotowicz, M.
Nash, P.
Prince, R.
Roberts, A.
Sambrook, P.
Dobnig, H.
Finkenstedt, G.
Hoefle, G.
Klaushofer, K.
Pecherstorfer, M.
Peichl, P.
Body, J.
Boonen, S.
Devogelaer, JP.
Geusens, P.
Kaufman, J.
Brenol£££João£££ J.,
Kochen, J.
Lederman, R.
Radominski, S.
Szejnfeld, V.
Zerbini, C.
Adachi, J.
Brown, J.
Choquette, D.
Hanley, D.
Josse, R.
Kendler, D.
Kremer, R.
Morin, F.
Olszynski, W.
Papaioannou, A.
KinYuen, C.
Chen, B.
Lin, S.
Casas, N.
Chalem, M.
Jaller, J.
Molina, J.
Aro, H.
Heikkinen, J.
Kröger, H.
Mäkinen, L.
Saltevo, J.
Salmi, J.
Välimäki, M.
Benhamou, CL.
Delmas, P.
Fardellone, P.
Werhya, G.
Allolio, B.
Felsenberg, D.
Happ, J.
Hartard, M.
Hensen, J.
Kaps, P.
Kekow, J.
Moericke, R.
Ortloff, B.
Schneider, P.
Wassenberg, S.
Leung, PC.
Balogh, A.
Gomor, B.
Hidvégi, T.
Koranyi, L.
Lakatos, P.
Poór, G.
Zsolt, T.
Pollak, RD.
Eshed, V.
Foldes, AJ.
Ish-Shalom, S.
Vered, I.
Weiss, M.
Adami, S.
Barone, A.
Bianchi, G.
Giannini, S.
Isaia, GC.
Luisetto, G.
Minisola, S.
Molea, N.
Nuti, R.
Ortolani, S.
Passeri, M.
Rubinacci, A.
Seriolo, B.
Sinigaglia, L.
Choi, WH.
Kang, MI.
Kim, GS.
Kim, HS.
Kim, YK.
Lim, SK.
Son, HY.
Yoon, HK.
Abud, C.
Garcia, P.
Jasqui, S.
Ochoa, L.
Orozco, J.
Santos, J.
Reid, I.
Elle£££Sigbjørn£££ S.,
Halse, J.
Høiseth, A.
Olav, H.
Røed£££Høivik Ingun£££ HI.,
Skag, A.
Stakkestad, J.
Syversen, U.
Badurski, J.
Czerwinski, E.
Lorenc, R.
Marcinowska-Suchowierska, E.
Sawicki, A.
Supronik, J.
Ailamazyan, E.
Benevolenskaya, L.
Dreval, A.
Dvoretsky, L.
Dyomina, R.
Mazurov, V.
Melnichenko, G.
Mkrtoumyan, A.
Orlov-Morozov, A.
Ostroumova, O.
Pikhlak, E.
Shemerovskaya, T.
Shostak, N.
Skripnikova, I.
Smetnik, V.
Tsyrlina, E.
Usova, G.
Zalevskaya, A.
Zazerskaya, I.
Zotkin, E.
Ljunggren, O.
Lofgren, J.
Palmér, M.
Saaf, M.
Stenström, M.
Hasler, P.
Lamy, O.
Lippuner, K.
Merlin, C.
Rizzoli, R.
Theiler, R.
Tyndall, A.
Uebelhart, D.
Chen, JF.
Chen, PQ.
Chin, LS.
Hwang, JS.
Yang, TS.
Jirapinyo, M.
Jirapinyo, M.
Sattaya, R.
Sriussadaporn, S.
Supasin, S.
Taechakraichana, N.
Wilawan, K.
Donnachie, H.
Eastell, R.
Fraser, W.
McLellan, A.
Reid, D.
Abruzzo, J.
Ackerman, R.
Adler, R.
Aloia, J.
Birbara, C.
Bode, B.
Bone, H.
Brandon, D.
Cauley, J.
Cosman, F.
Dionne, D.
Downs R.<Suffix>Jr</Suffix>,
Dreyfus, J.
Elinoff, V.
Emkey, R.
Fanciullo, J.
Fiske, D.
Genaro, P.
Gollapudi, M.
Gordon, R.
Hennessey, J.
Howard, P.
Johnson, K.
Johnston, C.
Kagan, R.
Kafka, S.
Kaine, J.
Klein, T.
Koltun, W.
Leboff, M.
Levine, B.
Lewiecki, EM.
Lewis, CE.
Licata, A.
Lillestol, M.
Lubin, B.
Malamet, R.
Mangione, A.
Matkovic, V.
Mehta, D.
Miller, P.
Miller, S.
Murphy, FT.
Nattrass, S.
Podlecki, D.
Recknor, C.
Rosen, C.
Rowe, D.
Rude, R.
Schnitzer, T.
Sherrer, Y.
Silverman, S.
Stephenson, K.
Troupin, B.
Tucci, J.
Villareal, R.
Watts, N.
Weinstein, R.
Weinstein, R.
Weitz, M.
White, R.
Liens vers les personnes
Liens vers les unités
ISSN
1433-2965
Statut éditorial
Publié
Date de publication
2010
Volume
21
Numéro
7
Première page
1277
Dernière page/numéro d’article
1285
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.
INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.
METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.
RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001).
CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.
METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.
RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001).
CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
Sujets
PID Serval
serval:BIB_9DE759B0F4B3
PMID
Date de création
2011-02-22T13:57:13.325Z
Date de création dans IRIS
2025-05-20T23:05:45Z